{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-26-001143","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2026-08-25T12:31:04+00:00","discovered_at":"2026-08-25T12:35:02.270216+00:00","generated_at":"2026-08-25T12:35:12.533471+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anavex Q3 net income $7.8M on comp reversal; advances FDA/EMA regulatory plans","bullets":["Q3 FY2026 net income $7.8M ($0.08/share) vs net loss $13.2M ($0.16/share) in Q3 FY2025.","Cash $118.3M at June 30, 2026 (vs $102.6M at Sept 30, 2025); funds ops into mid-late FY2028.","Reversal of $17.4M stock-based comp (G&A $7.5M, R&D $9.9M) from employee terminations, mainly former CEO.","Submitted all AD clinical data to FDA; FDA Phase 3 AD-005 design talks planned; EMA scientific advice received June 2026.","Rett Phase 3 RS-005 (~170 pts): FDA meeting requested on pediatric inclusion; Fragile X IND due Sept; 10-Q filings pending."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-001143","json":"https://secwatch.observer/filing/0001731122-26-001143.json","markdown":"https://secwatch.observer/filing/0001731122-26-001143.md","text":"https://secwatch.observer/filing/0001731122-26-001143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226001143/0001731122-26-001143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226001143/e7897_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-25T12:35:12.533471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}